Blood Clearance Kinetics, Biodistribution, and Radiation Dosimetry of a Kit-Formulated Integrin αvβ3-Selective Radiotracer 99mTc-3PRGD2 in Non-Human Primates
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
99mTc-3PRGD2 is a 99mTc-labeled dimeric cyclic RGD peptide with increased receptor binding affinity and improved kinetics for in vivo imaging of integrin αvβ3 expression in nude mouse model. To accelerate its clinical translation, we reported here the evaluation of the kit-formulated 99mTc-3PRGD2 in healthy cynomolgus primates for its blood clearance kinetics, biodistribution, and radiation dosimetry.
Healthy cynomolgus primates (4.1 ± 0.7 kg, n = 5) were anesthetized, and the venous blood samples were collected via a femoral vein catheter at various time points after injection of ~555 MBq of 99mTc-3PRGD2. Serial whole-body scans were performed with a dual-head single photon emission computed tomography system after administering ~555 MBq of 99mTc-3PRGD2 in the non-human primates, and the radiation dosimetry estimate was calculated.
99mTc-3PRGD2 could be easily obtained from freeze-dried kits with high radiochemical purity (>95%) and high specific activity (~5 Ci/μmol). 99mTc-3PRGD2 had a rapid blood clearance with less than 1% of the initial radioactivity remaining in the blood circulation at 60 min postinjection. No adverse reactions were observed up to 4 weeks after the repeated dosing. The whole-body images exhibited high kidney uptake of 99mTc-3PRGD2 and high radioactivity accumulation in the bladder, demonstrating the rapid renal clearance of this tracer. The highest radiation doses of 99mTc-3PRGD2 were found in the kidneys (13.2 ± 1.08 μGy/MBq) and the bladder wall (33.1 ± 1.91 μGy/MBq).
99mTc-3PRGD2 can be readily available using the kit formulation. This tracer is safe and well tolerated, and no adverse events occurred in non-human primates. Further clinical testing and translation of 99mTc-3PRGD2 for noninvasive imaging of integrin αvβ3 in humans are warranted.
- Hynes, RO (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69: pp. 11-25 CrossRef
- Brooks, PC, Clark, RA, Cheresh, DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: pp. 569-571 CrossRef
- Cai, W, Chen, X (2008) Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 49: pp. 113S-128S CrossRef
- Cai, W, Niu, G, Chen, X (2008) Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des 14: pp. 2943-2973 CrossRef
- Beer, AJ, Haubner, R, Sarbia, M, Goebel, M, Luderschmidt, S, Grosu, AL, Schnell, O, Niemeyer, M, Kessler, H, Wester, HJ (2006) Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin αvβ3 expression in man. Clin Cancer Res 12: pp. 3942-3949 CrossRef
- Haubner, R, Weber, WA, Beer, AJ, Vabuliene, E, Reim, D, Sarbia, M, Becker, KF, Goebel, M, Hein, R, Wester, HJ (2005) Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2: pp. e70 CrossRef
- Kenny, LM, Coombes, RC, Oulie, I, Contractor, KB, Miller, M, Spinks, TJ, McParland, B, Cohen, PS, Hui, AM, Palmieri, C (2008) Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 49: pp. 879-886 CrossRef
- Wang, L, Shi, J, Kim, YS, Zhai, S, Jia, B, Zhao, H, Liu, Z, Wang, F, Chen, X, Liu, S (2009) Improving tumor-targeting capability and pharmacokinetics of 99mTc-labeled cyclic RGD dimers with PEG4 linkers. Mol Pharm 6: pp. 231-245 CrossRef
- Liu, Z, Liu, S, Wang, F, Liu, S, Chen, X (2009) Noninvasive imaging of tumor integrin expression using 18F-labeled RGD dimer peptide with PEG4 linkers. Eur J Nucl Med Mol Imaging 36: pp. 1296-1307 CrossRef
- Liu, Z, Niu, G, Shi, J, Liu, S, Wang, F, Liu, S, Chen, X (2009) 68 Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin αvβ3 PET imaging. Eur J Nucl Med Mol Imaging 36: pp. 947-957 CrossRef
- Shi, J, Kim, YS, Zhai, S, Liu, Z, Chen, X, Liu, S (2009) Improving tumor uptake and pharmacokinetics of 64Cu-labeled cyclic RGD peptide dimers with Gly3 and PEG4 linkers. Bioconjug Chem 20: pp. 750-759 CrossRef
- Liu, S (2009) Radiolabeled cyclic RGD peptides as integrin αvβ3-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjugate Chem 20: pp. 2199-2213 CrossRef
- Beer, AJ, Haubner, R, Wolf, I, Goebel, M, Luderschmidt, S, Niemeyer, M, Grosu, AL, Martinez, MJ, Wester, HJ, Weber, WA (2006) PET-based human dosimetry of [18F]Galacto-RGD, a new radiotracer for imaging αvβ3 expression. J Nucl Med 47: pp. 763-769
- Kowalsky, RJ, Falen, SW (2004) Radiopharmaceuticals in nuclear pharmacy and nuclear medicine. American Pharmacist Association, Washington, D.C.
- Blood Clearance Kinetics, Biodistribution, and Radiation Dosimetry of a Kit-Formulated Integrin αvβ3-Selective Radiotracer 99mTc-3PRGD2 in Non-Human Primates
Molecular Imaging and Biology
Volume 13, Issue 4 , pp 730-736
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Integrin αvβ3
- 99mTc-labeled cyclic RGD peptides
- Industry Sectors
- Author Affiliations
- 1. Medical Isotopes Research Center, Peking University, 38 Xueyuan Road, Beijing, 100191, China
- 2. Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing, 100191, China
- 3. Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, 100730, China
- 4. School of Health Sciences, Purdue University, 550 Stadium Mall Drive, West Lafayette, IN, 47907, USA